Literature DB >> 2577718

Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome.

C B Nemeroff1, G Bissette, E Widerlov, H Beckmann, R Gerner, P J Manberg, L Lindstrom, A J Prange, W F Gattaz.   

Abstract

Neurotensin (NT) concentrations in cerebrospinal fluid (CSF) were measured by a sensitive and specific radioimmunoassay in psychiatric patients and age- and sex-matched normal controls. No increase in CSF NT concentrations was observed after antipsychotic drug treatment. CSF NT concentrations were significantly lower in one group of schizophrenic subjects. NT concentrations were unaltered in patients with depression, anorexia/bulimia, or premenstrual syndrome, and no rostral-caudal gradient for NT in CSF was evident. NT concentrations were not related to age or sex, and probenecid treatment did not alter CSF NT concentrations. Finally CSF NT concentrations were unaltered in paranoid schizophrenic subjects. These findings confirm and extend previous studies of CSF NT that showed certain patients with schizophrenia, nonparanoid type, have reduced CSF concentrations of this tridecapeptide.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2577718     DOI: 10.1176/jnp.1.1.16

Source DB:  PubMed          Journal:  J Neuropsychiatry Clin Neurosci        ISSN: 0895-0172            Impact factor:   2.198


  15 in total

Review 1.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

Review 2.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating.

Authors:  E B Binder; B Kinkead; M J Owens; C D Kilts; C B Nemeroff
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

4.  Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and beta-arrestin1-dependent mechanism.

Authors:  Dominic Thibault; Paul R Albert; Graciela Pineyro; Louis-Éric Trudeau
Journal:  J Biol Chem       Date:  2011-01-13       Impact factor: 5.157

Review 5.  Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment.

Authors:  F Brambilla
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

6.  Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.

Authors:  Shinnyi Chou; Collin Davis; Sean Jones; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2014-11-26       Impact factor: 3.533

7.  Sensorimotor gating in NTS1 and NTS2 null mice: effects of d-amphetamine, dizocilpine, clozapine and NT69L.

Authors:  Alfredo Oliveros; Michael G Heckman; Maria Del Pilar Corena-McLeod; Katrina Williams; Mona Boules; Elliott Richelson
Journal:  J Exp Biol       Date:  2010-12-15       Impact factor: 3.312

8.  Striatal dopamine receptor plasticity in neurotensin deficient mice.

Authors:  Lucy G Chastain; Hongyan Qu; Chase H Bourke; P Michael Iuvone; Paul R Dobner; Charles B Nemeroff; Becky Kinkead
Journal:  Behav Brain Res       Date:  2014-11-15       Impact factor: 3.332

9.  Association between neurotensin receptor 1 (NTR1) gene polymorphisms and schizophrenia in a Han Chinese population.

Authors:  Hui Ma; Yinglin Huang; Bo Zhang; Jingying Li; Yuan Wang; Xiaofeng Zhao; Qiu Jin; Gang Zhu
Journal:  J Mol Neurosci       Date:  2013-03-13       Impact factor: 3.444

10.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.